Capital increase of 3,854 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Company Registration No. 32266355
Copenhagen, Denmark, March 25, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) ("the Company"), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, announces that a share capital increase has been registered with the Danish Business Authority as a result of the exercise of Restricted Share Units by board members. A total of 3,854 shares of nominally DKK 1 each have been issued by the Company at a subscription price per Restricted Share Unit of DKK 61.1895.
Following the share capital increase, the total nominal share capital will be DKK 34,952,241, divided into 34,952,241 shares each with a nominal value of DKK 1. Each share carries one vote at Orphazyme's general meetings and accordingly the total number of voting rights of the company are 34,952,241. Updated Articles of Association can be found at www.orphazyme.com.
For additional information, please contact
Anders Vadsholt, Interim CEO & CFO +45 28 98 90 55
About Orphazyme A/S
Orphazyme is a late-stage biopharmaceutical company pioneering the Heat Shock Protein response for the treatment of neurodegenerative orphan diseases. The company is harnessing amplification of Heat Shock Proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction, including lysosomal storage diseases and neuromuscular degenerative diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease type C (NPC), Amyotrophic Lateral Sclerosis (ALS), Inclusion Body Myositis (IBM) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme’s shares are listed on Nasdaq U.S. (ORPH) and Nasdaq Copenhagen (ORPHA).
Arimoclomol is an investigational drug candidate that amplifies the production of Heat Shock Proteins (HSPs). HSPs can rescue defective misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is administered orally and has now been studied in seven phase 1, four phase 2 and one pivotal phase 2/3 trial. Arimoclomol is in clinical development for NPC, Gaucher Disease, IBM, and ALS. Arimoclomol has received orphan drug designation (ODD) for NPC, IBM, and ALS in the US and EU. Arimoclomol has received fast-track designation (FTD) from the U.S. Food and Drug Administration (FDA) for NPC, IBM and ALS. In addition, arimoclomol has received breakthrough therapy designation (BTD) and rare-pediatric disease designation (RPDD) from the FDA for NPC.
This company announcement may contain certain forward-looking statements, including in respect of the anticipated commercialization of arimoclomol. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could", and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements, including the risk that applicable regulatory authorities fail to approve arimoclomol on the anticipated timeline or at all. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
- 09-2021 Capital increase of 3,854 shares in Orphazyme as a result of the exercise of Restricted Share Units
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Jobindex A/S18.7.2021 14:30:51 CEST | Pressemeddelelse
Jobindex opjusterer forventningerne igen
Azerion8.7.2021 19:09:23 CEST | Pressemeddelelse
Azerion fortsætter sin europæiske ekspansion gennem opkøb af den svenske reklamespecialist Strossle
Azerion7.7.2021 20:36:03 CEST | Press release
Azerion continues its European expansion by acquiring Swedish advertising specialist Strossle
Royal UNIBREW A/S1.7.2021 21:13:45 CEST | Press release
Royal Unibrew overtager stærk nordisk drikkevarevirksomhed
FUJIFILM Holdings Corporation1.7.2021 17:01:20 CEST | Press release
Fujifilm launches a more comprehensive portfolio for Europe's healthcare community following the integration of Hitachi Diagnostic Imaging
Agillic A/S1.7.2021 09:01:32 CEST | Press release
Agillic welcomes new client Lindhardt & Ringhof Forlag, writing another chapter in the Egmont story
Agillic A/S16.6.2021 08:59:30 CEST | Press release
Agillic welcomes top form success stories in Germany with a new Partner "agilea" and a new client "CyberFitness"
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom